Below are the most recent publications written about "Spironolactone" by people in Profiles.
-
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, Gonz?lez A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2022 02 16; 8(2):149-156.
-
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, Gonz?lez A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021 02 11; 42(6):684-696.
-
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, D?ez J, Edelmann F, Girerd N, Gonz?lez A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC Heart Fail. 2021 04; 9(4):268-277.
-
Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina. 2018 May; 38(5):962-969.
-
Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. Retina. 2016 Mar; 36(3):611-8.
-
Salz DA, Pitcher JD, Hsu J, Regillo CD, Fineman MS, Elliott KS, Vander JF, Fischer DH, Spirn MJ. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015 Apr; 46(4):439-44.
-
Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs. 2010; 10(1):55-63.
-
Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2009 Jan 27; 119(3):398-407.
-
Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008 Feb; 10(2):157-63.
-
Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006 Nov; 147(11):5363-73.